MECHANISMS OF HUMAN LUNG HYPERSENSITIVITY REACTIONS

Information

  • Research Project
  • 3130418
  • ApplicationId
    3130418
  • Core Project Number
    R01AI020634
  • Full Project Number
    5R01AI020634-08
  • Serial Number
    20634
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/1988 - 36 years ago
  • Project End Date
    12/31/1992 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    1/1/1991 - 33 years ago
  • Budget End Date
    12/31/1991 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    8
  • Suffix
  • Award Notice Date
    12/27/1990 - 33 years ago
Organizations

MECHANISMS OF HUMAN LUNG HYPERSENSITIVITY REACTIONS

This project's long term objective is a better understanding of the mechanisms and control of human lung hypersensitivity disorders and asthma. Studies will focus on the central cell of lung hypersensitivity, the human lung mast cell (HLMC). The HLMC, by virtue of its anatomic localization, elaboration of potent chemical mediators upon stimulation, and the effects of these mediators on cell and tissue targets, can produce the pathophysiologic manifestations of these disorders: airway constriction, edema, and hypersecretion. The studies involve enzymatically dispersing human lung into a single cell suspension, and separating HLMC by elutriation and flotation through step-gradients into morphologically and functionally distinct subpopulations based on their diameters and densities, respectively. The density-step also results in purification of diameter separated HLMC. By taking advantage of typical histochemical profiles found after diameter and density separations, we have also recently developed methods to isolate HLMC subpopulations akin to the histochemically distinct subpopulations classically described in the rodent. Once isolated, HLMC subpopulations will be examined with respect to ultrastructure, content and release of mediators (including a recently discovered mast cell elastase), and sensitivities to relevant triggering stimuli. These stimuli include a newly described alvolar macrophage-derived releasing factor. Also, selective responsiveness of subpopulations to pharmacologic modulation of release will be examined. The agents to be tested include B-adrenergic agonists, inhibitors of arachidonic acid metabolism, membrane cholesterol binders, and cholesterol biosynthesis inhibitors. The crucial role of membrane cholesterol and phospholipids in release will be explored in purified HLMC through quantitative measurements of cholesterol and phospholipid turnover during activation-secretion. Novel mechanisms of HLMC release inhibition, through manipulation of the membrane lipid micro- environment, will also be studied.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
  • Funding Mechanism
  • Study Section
    PTHA
  • Study Section Name
    Pathology A Study Section
  • Organization Name
    HAHNEMANN UNIVERSITY
  • Organization Department
  • Organization DUNS
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19129
  • Organization District
    UNITED STATES